Inclusion Body Myositis Life Expectancy
Treatment with drugs that contain the immune system has been tried in inclusion body myositis but in general has not been effective. Some physicians may try corticosteroids or other medications that change the immune response if the patient wishes this Treatment of Inclusion Body Myositis, but many feel that side effects outweigh any subtle benefits that might occur with these drugs in IBM.
Inclusion body myositis is commonly a slowly progressive disease, and life expectancy is not radically affected. Most people with inclusion body myositis remain able to walk, although they may require a cane or wheelchair for long distances. Some are more extremely affected, becoming gradually more disabled and needing wheelchairs full time within 10 or 15 years of the first symptoms.
There are no data currently accessible for the incidence of inclusion body myositis globally, although it has been reported in Europe and Asia. Inclusion body myositisis thought to explanation for approximately 15–20% of all cases of inflammatory myositis in the US. Rate of deaths is difficult to assess, as most people with inclusion body myositis are older and may die of additional coexisting medical problems. There is no race prevalence, but it is uncommon among African Americans. The male and female ratio is 3:1 and most affected individuals are 50 years or older. However, inclusion body myositis does not seem to affect life expectancy.